Thymosin beta 10 (TMSB10) is a small, conserved protein belonging to the β-thymosin family, which regulates actin dynamics by sequestering monomeric actin (G-actin) and influencing cytoskeletal organization. TMSB10 is widely expressed in mammalian tissues, particularly in immune cells, neurons, and certain epithelial cells, where it plays roles in cell motility, differentiation, and inflammatory responses. Its dysregulation has been linked to various pathological conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. In cancer, TMSB10 is often overexpressed in tumors such as hepatocellular carcinoma, glioblastoma, and colorectal cancer, where it promotes metastasis, angiogenesis, and chemoresistance by modulating cytoskeletal remodeling and signaling pathways like PI3K/AKT and MAPK.
Antibodies targeting TMSB10 are essential tools for studying its expression, localization, and functional mechanisms. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess TMSB10 levels in tissues or cell lines, aiding in cancer prognosis and mechanistic research. Some antibodies are designed to detect specific post-translational modifications or isoforms. Commercial TMSB10 antibodies are typically raised in rabbits or mice, with validation data confirming cross-reactivity in human, mouse, and rat samples. Their applications extend to exploring TMSB10's role in non-cancer contexts, such as neuroprotection or immune regulation, highlighting their versatility in both basic and clinical research.